3-(4-5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium and Liver-Neoplasms

3-(4-5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium has been researched along with Liver-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for 3-(4-5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium and Liver-Neoplasms

ArticleYear
Effect of hyperthermia on liver cell lines: important findings for thermal therapy in hepatocellular carcinoma.
    Anticancer research, 2011, Volume: 31, Issue:5

    Hepatocellular carcinoma is the fifth most common malignant tumour, with a high mortality rate. This study aimed to investigate the effect of hyperthermia on HepG2 and LX-1 cell lines to gain more information on thermal treatment of liver tumours.. The cell lines HepG2, LX-1 and their co-cultures were heated from 55°C to 85°C for different time spans. After heat exposure, metabolic activity was measured immediately, and after 24 h and 48 h using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) test to assess how many cells had survived heating.. Our results show highly significant differences between the temperature tolerance of HepG2 and LX-1 cells. Alone, HepG2 cells are most sensitive to heat-induced cell death, their sensitivity decreased with rising percentages of LX-1 cells in the co-culture.. Our results suggest that the outcome of thermal cancer therapy is dependent on the temperature and the grade of fibrosis in the treated livers.

    Topics: Carcinoma, Hepatocellular; Coculture Techniques; Fever; Hot Temperature; Humans; Liver; Liver Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured

2011
Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
    Human pathology, 2009, Volume: 40, Issue:9

    Polycomb gene products play a crucial role in the development of highly malignant phenotypes and aggressive cancer progression in a variety of cancers; however, their role in hepatocellular carcinoma remains unclear. First, we analyzed the impact of EZH2 and BMI1 modulation on cell growth of HepG2 cells. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assays revealed marked growth inhibition after EZH2 or BMI1 knockdown. In addition, simultaneous knockdown of these 2 genes further augmented cell growth inhibitory effects. Next, we conducted immunohistochemical assessment of 86 hepatocellular carcinoma surgical specimens, evaluating the correlation between EZH2 and BMI1 protein expression and clinicopathologic features. High-level EZH2 and BMI1 expression was detected in 57 (66.3%) and 52 tumor tissues (60.5%), respectively. Among these, 48 tumor tissues (55.8%) showed colocalization of EZH2 and BMI1 in almost all tumor cells. The cumulative recurrence rate, but not survival rate, was significantly higher in patients positive for EZH2 (P = .029) and BMI1 (P = .039) than in their negative counterparts, as determined by Kaplan-Meier analysis. These data indicate that EZH2 and BMI1 may cooperate in initiation and progression of hepatocellular carcinoma.

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Fluorescent Antibody Technique, Indirect; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Nuclear Proteins; Polycomb Repressive Complex 1; Polycomb Repressive Complex 2; Polycomb-Group Proteins; Proto-Oncogene Proteins; Repressor Proteins; RNA, Small Interfering; Tetrazolium Salts; Thiazoles; Transcription Factors

2009